CDS-Humanized Target Gene Mouse Models
Cyagen develops CDS-humanized mouse models by replacing endogenous mouse coding sequences with human CDS regions under native mouse regulation. Test clinical antibodies, ADCs and small molecules against the true human target, enabling more relevant target validation and efficacy studies while accelerating preclinical research and therapeutic development.
Flexible Humanization
Humanize selected coding regions or the full CDS based on therapeutic binding sites, protein function, and study requirements.
Accelerated Model Development
Humanize a single exon, a functional domain or the full CDS, with up to 50% faster model delivery than conventional methods.
Target-Specific Validation Data
Test oncology, immunotherapy and hematologic drugs in pre-validated CDS-humanized models with clinically relevant drug responses.
Overview
Product
FAQs
What Is a CDS-Humanized Mouse Model?
CDS-humanized mouse models are genetically engineered to express fully or partially humanized target proteins. Depending on the design, selected mouse coding regions are replaced or modified using corresponding human sequences. Regulatory elements and expression patterns vary by model and should be evaluated using target-specific validation data.
This approach can be particularly useful for therapeutics that recognize human-specific protein regions, for example an antibody that recognizes a human-specific epitope, or a small molecule that binds a pocket that differs between species. It enables studies with the clinical candidate rather than a mouse-reactive surrogate, improving the translational value of preclinical data.
Cyagen offers two complementary target-humanization strategies. The right choice depends on how your therapeutic engages the target.
Only the coding sequence is humanized (the full CDS, selected exons or a functional domain), while the mouse promoter and UTRs are retained. This is the efficient choice for drugs that act on the protein: antibodies, ADCs, bispecifics, fusion proteins, small molecules and cell therapies. Key question answered: does my drug bind and act on the human protein in vivo?
The full-length human gene is introduced, including introns and, in many models, the 5′ and 3′ UTRs, supporting human splicing and RNA-level regulation. This is required for drugs that act on human DNA or RNA sequences: ASOs, siRNAs, splice-switching drugs, base or prime editing, and AAV/LNP gene therapies.
Learn more about HUGO-GT™ humanized mice.
Rule of thumb: CDS humanization is often suitable when the study primarily requires a humanized protein target. Full-gene humanization may be preferable when therapeutic activity depends on human-specific genomic sequences, transcript structures, or regulatory elements. The optimal strategy should be determined by the therapeutic mechanism of action and the required experimental endpoints.
This approach can be particularly useful for therapeutics that recognize human-specific protein regions, for example an antibody that recognizes a human-specific epitope, or a small molecule that binds a pocket that differs between species. It enables studies with the clinical candidate rather than a mouse-reactive surrogate, improving the translational value of preclinical data.
CDS Humanization vs. Full-Gene Humanization (HUGO-GT™): Which Do You Need?
Cyagen offers two complementary target-humanization strategies. The right choice depends on how your therapeutic engages the target.
CDS-Humanized Mice
Only the coding sequence is humanized (the full CDS, selected exons or a functional domain), while the mouse promoter and UTRs are retained. This is the efficient choice for drugs that act on the protein: antibodies, ADCs, bispecifics, fusion proteins, small molecules and cell therapies. Key question answered: does my drug bind and act on the human protein in vivo?
HUGO-GT™ Full-Gene Humanized Mice
The full-length human gene is introduced, including introns and, in many models, the 5′ and 3′ UTRs, supporting human splicing and RNA-level regulation. This is required for drugs that act on human DNA or RNA sequences: ASOs, siRNAs, splice-switching drugs, base or prime editing, and AAV/LNP gene therapies.
Learn more about HUGO-GT™ humanized mice.
Rule of thumb: CDS humanization is often suitable when the study primarily requires a humanized protein target. Full-gene humanization may be preferable when therapeutic activity depends on human-specific genomic sequences, transcript structures, or regulatory elements. The optimal strategy should be determined by the therapeutic mechanism of action and the required experimental endpoints.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Oncology CRO Platform
End-to-end preclinical oncology support from models to IND data
Cardiovascular CRO Platform
IND-ready studies using genetic and induced disease models
Gene Therapy CRO Platform
AI-guided AAV design and full-spectrum preclinical validation
Autoimmune & Inflammation
Advancing autoimmune drug discovery with models and efficacy data.
Rodent Breeding
Scalable colony expansion with full genotyping support
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.